Executive Summary
Dell Federal Systems secured a $107.7M obligated BPA call (up to $182.7M with options) from NIH for enterprise software licenses, with $71M already outlayed, signaling strong federal health IT demand and multi-year revenue for Dell. This single large award underscores Dell's entrenched position in government software procurement amid full and open competition.
Investors should monitor option exercises for an additional ~$75M upside, balanced against firm fixed-price execution risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Federal IT & Cybersecurity Contracts digest from March 04, 2026.
Investment Signals (1)
- Major NIH Software BPA Award (HIGH)▲
Dell Federal awarded $107.7M obligation (70% outlayed) under multi-year enterprise license agreement, providing revenue visibility through 2027-2028.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Firm fixed-price structure exposes Dell to cost overruns without reimbursement; full value depends on future BPA calls and option exercises.
Opportunities (1)
- ◆
~$75M in unobligated options plus potential 1-year extension to 2028.
Sector Themes (1)
- ◆
Large-scale enterprise license awards to non-small businesses like Dell under full competition highlight sustained NIH investment in perpetual software for research.
Watch List (1)
- 👁
{"entity"=>"Dell Federal Systems L.P.", "reason"=>"Single record dominates period with $107.7M obligation and $75M options at risk of non-exercise.", "trigger"=>"Q2 2026 option notices or outlay acceleration beyond $71M"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Federal IT & Cybersecurity Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals